Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 6/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265442 | 1.00 | HDAC6 (0.74) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30483213 | 0.98 | HDAC6 (0.72) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17802641 | 0.98 | HDAC6 (0.72) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL30483184 | 0.90 | HDAC6 (0.62) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1299107 | 0.87 | HDAC6 (0.56) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29424777 | 0.87 | HDAC6 (0.56) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17802639 | 0.86 | HDAC6 (0.55) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1608633 | 0.85 | HDAC6 (1.00) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30265139 | 0.84 | L3MBTL1 (0.65) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1055278 | 0.84 | HDAC6 (0.74) | HDAC6KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-113004252-B | Aryl imidazole derivative and application thereof | 江苏先声药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| CN-115551864-A | Substituted tricyclic amides, analogs thereof, and methods of using the same | 爱彼特生物制药公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2016089648-A1 | BACH 1 INHIBITORS IN COMBINATION WITH NRF2 ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | VTV THERAPEUTICS LLC (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2014074805-A1 | SELECTIVE TARGETING OF CANCER STEM CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1117651-A1 | NEW BIS-BENZIMIDAZOLES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020401-A1 | NEW BIS-BENZIMIDAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | HDAC6 661/4885KMT2A 1474/4885NPC1 417/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | HDAC6 154/4885KMT2A 1986/4885NPC1 322/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | HDAC6 1346/4885KMT2A 669/4885NPC1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.